CANTOURAGE GROUP SE
Commented by Fabian Lorenz on September 5th, 2024 | 09:15 CEST
Bargain alert in Biotech, AI, Cannabis: Evotec, Cantourage, BlockchainK2 share instead of Nvidia?
The weak late summer months on the stock market often offer opportunities for bargain hunters - including at the moment and away from the large caps. For instance, Nvidia has already lost around 30% from its all-time high, but historically a drop of 50% or more is not uncommon for this AI high-flyer. It is, therefore, worth taking a look at fallen small and mid-caps. For example, Cantourage shares gained more than 10% yesterday alone. Is there more to come for the cannabis stock? BlockchainK2 shares are also ripe for a price surge. The SaaS platform for financial service providers offers cost and efficiency benefits thanks to blockchain and AI. The sentiment for fintechs - look at PayPal - is currently brightening noticeably, and BlockchainK2 is a takeover candidate. The same could be said for Evotec, or is there a risk of a slide to EUR 4? In any case, the Company is not finding any peace.
Read
Commented by Nico Popp on October 11th, 2023 | 07:50 CEST
New iPhone moment? Apple, NVIDIA, Cantourage
On January 9, 2007, the world changed. That was when Apple introduced its iPhone. Smartphones with touchscreens were previously unknown, but today? Hardly anyone can do without smartphones, tablets and the like! For Apple, the iPhone was the product that changed many things and made the Californians the most valuable company in the world for a time. At the end of 2022, ChatGPT was the next technology to change the world. NVIDIA's stock has been soaring ever since. We highlight NVIDIA and Apple and examine what revolution could change everything for the German company Cantourage.
Read
Commented by Juliane Zielonka on October 6th, 2023 | 08:00 CEST
Cantourage Group SE, Amazon, British American Tobacco: Stockpiling between medical innovation and dividend history
The Berlin-based company Cantourage, which specializes in the distribution of medical cannabis, is experiencing promising growth in the booming medical cannabis market. The global market for the plant's medical use is expected to have reached around USD 12.92 billion since 2021 and is projected to grow to USD 23.97 billion by 2028 at an average CAGR of 13.16%. Cantourage continues to expand its strong international distribution network with its innovative Fast Track Access platform. The Company even has a chance to win in the "Most Innovative Business Strategy" category at the 2023 European Small and Midcap Awards in November. Unlike other medical cannabis producers, Cantourage does not grow its own plants. Just as Uber doesn't own cars and AirBnB doesn't own hotels, Cantourage relies on strong distribution power in Healthcare. Healthcare is also attractive to Amazon again. Through mergers and acquisitions involving an online pharmacy and a thriving network of doctors, the US company is now investing in generative AI beyond ChatGPT. Meanwhile, historic dividend king British American Tobacco faces decline and bans.
Read
Commented by Armin Schulz on September 20th, 2023 | 08:25 CEST
Canopy Growth, Cantourage Group, Aurora Cannabis - Will the price fireworks come after legalization?
For a long time, there was little reason for cannabis investors to rejoice. However, since Bloomberg reported that the US Department of Health and Human Services has asked the DEA to downgrade cannabis from Schedule 1 to Schedule 3, hopes for legalization are reviving. This downgrade would mean that cannabis would no longer be on par with heroin or other hard drugs. Democrats also want to give businesses in this sector legal access to bank accounts. In Germany, the traffic lights have approved Health Minister Lauterbach's plans to legalize cannabis. We, therefore, look at three companies that are betting on cannabis.
Read
Commented by André Will-Laudien on September 11th, 2023 | 07:30 CEST
The next steps towards cannabis THC legalization are underway! Canopy, Tilray and BioNTech are taking the lead, and Cantourage Group is experiencing dynamic growth
Cannabis has been decriminalized in some countries but legalized in only a few states. In the US, cannabis is fully legalized in states such as California but outright banned in others such as Texas. While medical use is slowly catching on, the use as an intoxicant and cultivation for personal use remains controversial. Stronger momentum could be sparked by the US Department of Health and Human Services (HHS). The authorities are open to a downgrading of the degree of danger in the categorization of the US Drug Enforcement Administration (DEA). We are talking about two steps from Schedule I to Schedule III, which no longer puts THC on a par with common drugs such as heroin, ecstasy or LSD but classifies them as substances with comparatively little psychological dependence. That would be a revolutionary step. Which stocks can benefit?
Read
Commented by Stefan Feulner on September 6th, 2023 | 07:30 CEST
Cannabis stocks showing signs of life - Aurora Cannabis, Cantourage Group, Canopy Growth
In recent years, the once-hyped cannabis industry was considered a true capital destroyer. Even market leaders like Aurora Cannabis, Tilray, or Canopy Growth saw their stock values plummet by more than 90% at their peak. A letter from the US Department of Health and Human Services has sparked the first signs of a potential revival, which could eventually lead to a sustainable bottoming out in the long run.
Read
Commented by Fabian Lorenz on August 30th, 2023 | 08:30 CEST
Better than Nel & Co.? Megatrend shares Redcare Pharmacy and Cantourage Group recommended as buy
Hydrogen has electrified investors for years. But pure-plays like Plug Power and Nel & Co. are struggling to get their numbers in order and are far from profitable business models. As a result, these shares are not much fun at the moment, and analysts see further downside potential. In such a situation, it is worth taking a look at other megatrend stocks. Redcare Pharmacy (formerly Shop Apotheke) is benefiting from online pharmacy and e-prescription trends. The share has already more than doubled this year. Investors can profit from the cannabis trend with the German Cantourage Group. The Company is growing strongly and the share price has come to rest (before the storm). Both shares are recommended to buy by analysts.
Read
Commented by Juliane Zielonka on August 17th, 2023 | 07:10 CEST
Cantourage, Amazon, Bayer: Young entrants soaring, old players in reorientation
The time has finally come in Germany: the federal government has given the green light for the private use of cannabis. Since 2017, doctors in Germany have been allowed to prescribe cannabis as a therapeutic agent. The growing market in this segment has been recognized by the team at Cantourage, which focuses on the medical production of active ingredients from the hemp plant. The leadership of Bayer could use some relief. Analysts at Berenberg Bank have put the Leverkusen-based company's balance sheet through its paces and discovered a few things that have now downgraded Bayer's stock from Buy to Hold. Amazon's Cloud Business takes another step forward. The Company's in-house AI is moving into the documentation of medical health reports. Find out what it is all about here.
Read
Commented by Stefan Feulner on July 31st, 2023 | 09:50 CEST
BASF, Cantourage Group, Palantir - Now the analysts speak out
Currently, it is high noon for the release of first-half 2023 earnings. Despite all the uncertainties regarding geopolitical and fiscal policy, the majority of companies surprised positively. As a result, the Dow Jones, DAX, Nasdaq and others were able to climb to new highs for the year. Analysts also see further upside potential for many companies, which could accelerate the rally in the coming weeks.
Read
Commented by André Will-Laudien on July 19th, 2023 | 08:00 CEST
Cannabis 3.0 - will profits be made now? Canopy and Tilray under pressure, Cantourage Group positioned superbly
For a few days now, a long-neglected stock market segment has been attracting attention again: the cannabis industry. The North American industry protagonists Canopy and Tilray have recently attracted some stock market turnover again, but skepticism remains high. For those investors who did not exit in time, they had to write off around 95% of their investment in the last 2 years, and experts suspect that the revaluation of the former high-flyers is not yet complete. We take a look at the nebulous scenery of hemp speculation.
Read